Nanotechnology and medical devices: Risk, regulation and ‘meta’ registration

Grange, Simon; Chettiar, Kris; Arestu, Mateen; Pilarski, Patrick M.; Smitham, Peter; Loizidou, M; Jell, G

doi:10.1260/1708-5284.10.3.191

Cited by 8 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomedical applications must modify the surface of magnetic NPs to make them more stable before they are used for drug delivery to improve the limitations of these NPs, which include their destabilization effect and non-specific uptake by the RES; the size of magnetic NPs is also limited by the main immunogenic region [ 28 , 29 , 30 , 31 ]. Surface modification is required for biomedical applications to begin coating them with stimuli-responsive magnetic NPs that respond when exposed to external stimuli and can generate physicochemical changes in the structure that favor controlled drug release or release at a specific place [ 32 , 33 , 34 ].…”

Section: Introductionmentioning

confidence: 99%

Formulation and Characterization of Poly (Ethylene Glycol)-Coated Core-Shell Methionine Magnetic Nanoparticles as a Carrier for Naproxen Delivery: Growth Inhibition of Cancer Cells

Yeganeh

Yousefi

et al. 2022

Cancers

View full text Add to dashboard Cite

An efficient and selective drug delivery vehicle for cancer cells can remarkably improve therapeutic approaches. In this study, we focused on the synthesis and characterization of magnetic Ni1−xCoxFe2O4 nanoparticles (NPs) coated with two layers of methionine and polyethylene glycol to increase the loading capacity and lower toxicity to serve as an efficient drug carrier. Ni1−xCoxFe2O4@Methionine@PEG NPs were synthesized by a reflux method then characterized by FTIR, XRD, FESEM, TEM, and VSM. Naproxen was used as a model drug and its loading and release in the vehicles were evaluated. The results for loading efficiency showed 1 mg of Ni1−xCoxFe2O4@Methionine@PEG NPs could load 0.51 mg of the naproxen. Interestingly, Ni1−xCoxFe2O4@Methionine@PEG showed a gradual release of the drug, achieving a time-release up to 5 days, and demonstrated that a pH 5 release of the drug was about 20% higher than Ni1−xCoxFe2O4@Methionine NPs, which could enhance the intracellular drug release following endocytosis. At pH 7.4, the release of the drug was slower than Ni1−xCoxFe2O4@Methionine NPs; demonstrating the potential to minimize the adverse effects of anticancer drugs on normal tissues. Moreover, naproxen loaded onto the Ni1−xCoxFe2O4@Methionine@PEG NPs for breast cancer cell lines MDA-MB-231 and MCF-7 showed more significant cell death than the free drug, which was measured by an MTT assay. When comparing both cancer cells, we demonstrated that naproxen loaded onto the Ni1−xCoxFe2O4@Methionine@PEG NPs exhibited greater cell death effects on the MCF-7 cells compared with the MDA-MB-231 cells. The results of the hemolysis test also showed good hemocompatibility. The results indicated that the prepared magnetic nanocarrier could be suitable for controlled anticancer drug delivery.

show abstract